Use of blockbuster anti-obesity drugs like Wegovy and Zepbound is growing, with about 1 in 8 adults in the U.S. saying they currently take the medications. But experts say the drugs alone aren't the answer. It takes lifestyle changes, too, including a healthy diet, physical exercise, adequate sleep and stress management to reap the biggest benefits from GLP-1s. The clinical trials of the drugs included structured lifestyle changes, which are advised along with every prescription. Experts say users should eat protein, drink water and exercise for about an hour each day.
Meals and snacks with "GLP-1 Friendly" labels on the packaging are becoming more common as a growing number of Americans try obesity drugs like Wegovy and Zepbound to lose weight. Nestle and Conagra have put the labels on some of their frozen meals. Food chains like Smoothie King and Chipotle are introducing menu items targeting GLP-1 users. Dietitians say the nutritional needs of people taking the medications aren't that different from the general population's. They need to get enough protein to maintain muscle mass as they lose weight. Fiber is important to prevent constipation. Dietitians recommend reading food labels carefully. Some products marketed to GLP-1 users contain high amounts of saturated fat and sodium.
The Trump administration says pharmaceutical companies have agreed to slash the Medicare prices for 15 prescription drugs after months of negotiations and that it's expected to produce billions in savings for older adults. But the net prices unveiled Tuesday aren't what Medicare recipients will pay at their pharmacy counters because those final amounts will depend on each individual's plan and how much they spend annually on prescriptions. Health Secretary Robert F. Kennedy Jr. touted the deals as part of efforts to address affordability concerns. The negotiation program is mandated by law and began under the Biden administration.
Pricey prescriptions and nagging medical costs are swamping some insurers and employers, which means patients may start paying more next year. Health insurance will grow more expensive in many corners of the market in 2026, and some coverage may shrink. That could leave patients exposed to more costs for doctor visits and prescription coverage changes. Price changes could be especially stark in individual coverage marketplaces, where insurers also are predicting the end of some government support that helps people buy coverage. Expensive gene therapies and diabetes and obesity treatments are pressuring prescription coverage.
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many. Coverage also continues to shift or restrict how patients get prescriptions. Doctors say the patchy coverage and costs force them to get creative in treating patients. But there's hope that prices for the injectable drugs may fall more in the future, especially once pill versions enter the market.
Supplies of high-demand obesity treatments are improving, but that doesn't mean they're easier to get. Many employers and health insurers are scaling back coverage of Wegovy or Zepbound and a key government program, Medicare, doesn't cover the drugs for obesity. Clouding the picture even further, some big employers are adding coverage. But their commitment isn't guaranteed. Treatment prices that can top hundreds of dollars monthly even after discounts make it hard for many to afford these drugs on their own. That makes the life-changing weight-loss that patients seek largely dependent on the coverage they have and how long it lasts.
